Eton Pharmaceuticals (NASDAQ:ETON) Upgraded to Strong-Buy at Zacks Research

Zacks Research upgraded shares of Eton Pharmaceuticals (NASDAQ:ETON) from a hold rating to a strong-buy rating in a report published on Thursday morning,Zacks.com reports.

Several other research firms have also recently issued reports on ETON. B. Riley Financial increased their price objective on shares of Eton Pharmaceuticals from $26.00 to $31.00 and gave the company a “buy” rating in a report on Friday. Craig Hallum boosted their target price on Eton Pharmaceuticals from $30.00 to $35.00 and gave the stock a “buy” rating in a report on Friday. HC Wainwright upped their target price on Eton Pharmaceuticals from $37.00 to $52.00 and gave the stock a “buy” rating in a research report on Friday. Wall Street Zen upgraded Eton Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Eton Pharmaceuticals in a report on Thursday, January 22nd. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Eton Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $39.33.

Eton Pharmaceuticals Price Performance

Shares of NASDAQ ETON opened at $22.32 on Thursday. The stock has a market cap of $598.58 million, a P/E ratio of -123.99 and a beta of 1.19. The firm’s 50-day simple moving average is $16.72 and its 200 day simple moving average is $17.38. Eton Pharmaceuticals has a fifty-two week low of $11.09 and a fifty-two week high of $23.00. The company has a quick ratio of 1.25, a current ratio of 1.63 and a debt-to-equity ratio of 1.19.

Eton Pharmaceuticals (NASDAQ:ETON) last released its earnings results on Thursday, March 19th. The company reported $0.05 EPS for the quarter, missing the consensus estimate of $0.12 by ($0.07). Eton Pharmaceuticals had a negative net margin of 5.75% and a negative return on equity of 2.66%. The company had revenue of $21.28 million for the quarter, compared to analyst estimates of $20.58 million. Equities analysts expect that Eton Pharmaceuticals will post -0.14 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Millennium Management LLC lifted its position in shares of Eton Pharmaceuticals by 156.3% in the 1st quarter. Millennium Management LLC now owns 355,929 shares of the company’s stock valued at $4,620,000 after acquiring an additional 217,042 shares in the last quarter. Goldman Sachs Group Inc. boosted its position in shares of Eton Pharmaceuticals by 34.9% in the first quarter. Goldman Sachs Group Inc. now owns 175,220 shares of the company’s stock worth $2,274,000 after buying an additional 45,341 shares during the period. Jane Street Group LLC grew its holdings in shares of Eton Pharmaceuticals by 49.1% during the first quarter. Jane Street Group LLC now owns 95,919 shares of the company’s stock valued at $1,245,000 after buying an additional 31,596 shares in the last quarter. Envestnet Asset Management Inc. raised its position in Eton Pharmaceuticals by 33.1% during the second quarter. Envestnet Asset Management Inc. now owns 23,050 shares of the company’s stock valued at $328,000 after buying an additional 5,734 shares during the period. Finally, Geode Capital Management LLC lifted its stake in Eton Pharmaceuticals by 98.8% in the 2nd quarter. Geode Capital Management LLC now owns 592,865 shares of the company’s stock worth $8,450,000 after acquiring an additional 294,617 shares in the last quarter. 27.86% of the stock is owned by hedge funds and other institutional investors.

Eton Pharmaceuticals News Summary

Here are the key news stories impacting Eton Pharmaceuticals this week:

• Positive Sentiment: Several brokerages raised price targets and reiterated buy ratings (HC Wainwright to $52, B. Riley to $31, Craig Hallum to $35), increasing upside expectations and driving bullish investor sentiment. Analyst Upgrades
• Positive Sentiment: Eton acquired U.S. rights to HEMANGEOL, expanding its commercial portfolio in a specialty/rare-disease area and creating a clearer near-term revenue pathway. Eton Pharmaceuticals Acquires U.S. Rights to HEMANGEOL
• Positive Sentiment: Market commentary highlights a meaningful consensus upside — Zacks notes analysts’ mean targets imply roughly a 49% rally — reinforcing the bullish narrative from upgraded targets. Does Eton Pharmaceuticals Have the Potential to Rally 49.25%?
• Neutral Sentiment: Earnings call and company commentary emphasized record revenue growth and commercial progress, which supports the growth story but did not fully offset margin pressures. Q4 2025 Earnings Call Summary
• Neutral Sentiment: Reported short-interest data for March appears anomalous/flat (0 shares reported and a 0.0 days-to-cover), so it’s unlikely to be a material driver of today’s move. (Data looks unreliable.)
• Negative Sentiment: Q4 results: revenue beat slightly ($21.28M vs. $20.58M est.) but EPS missed ($0.05 vs. $0.12 est.); the company still reports negative net margin and negative ROE, raising profitability concerns. Eton Pharmaceuticals Reports Q4 & Full-Year 2025 Results
• Negative Sentiment: Analyst coverage also flagged the EPS miss in headlines (Zacks: earnings lag estimates), which could cap near-term sentiment until margins improve. Eton Q4 Earnings Lag Estimates

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.